Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialCatalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market Share XCatalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trialhttps://pharmaphorum.com/news/catalysts-rival-to-novoseven-hits-the-mark-in-phase-2-haemophilia-trial/